HG6.F Mayne Pharma Group Limited

Healthcare Pharmaceuticals Frankfurt Exchange
1.98 EUR
Close of Nov 12, 2026
1.13 3.30
Market cap
EUR 162M
P/E
11.0x
P/B
0.67x
ROE
6.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jun 2026.

Is HG6.F undervalued?

Graham number
Price1.98
Graham value3.47
Discount42.9%

HG6.F trades 42.9% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Mayne Pharma Group Limited fundamental analysis

No fundamental analysis for Mayne Pharma Group Limited yet.

Mayne Pharma Group Limited stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Mayne Pharma Group Limited

Mayne Pharma Group Limited, a specialty pharmaceutical company, focuses on the commercialization of women's health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. It operates through three segments: Women's Health, Dermatology, and International. The company provides oral drug delivery systems, as well as contract development and manufacturing services to third party customers. It also distributes speci…

Full company profile